What question did this study set out to answer?

This trial aims to assess the effectiveness of minimally invasive surfactant therapy (MIST) compared to the InSurE method in treating preterm infants with respiratory distress syndrome (RDS).

February 8, 2026Journal of Neonatology

Minimally Invasive Surfactant Therapy Versus InSurE in Preterm Neonates of 28-34 Weeks of Gestation with Respiratory Distress Syndrome: A Randomised Controlled Trial

View Full Paper

Ask AI

Bookmark

Authors

RSRavi SuwethaaGovernment Vellore Medical College TOThangamani OviyaveenaGovernment Vellore Medical College SSSrinivasan SrideviGovernment Medical College

Discussion

Member takes

Implication

Randomised trial shows minimally invasive surfactant therapy reduces complications in preterm neonates with respiratory distress syndrome, suggesting a better clinical practice.

Key Points

This trial aims to assess the effectiveness of minimally invasive surfactant therapy (MIST) compared to the InSurE method in treating preterm infants with respiratory distress syndrome (RDS).
Enrolled 192 preterm infants (28-34 weeks gestation) with RDS.
Managed neonates with nasal continuous positive airway pressure (nCPAP) and titrated oxygen levels.
Randomised infants needing high oxygen levels (FiO2 > 40%) to receive either MIST or InSurE surfactant administration.
Assessed subsequent clinical outcomes.
MIST approach resulted in a lower need for mechanical ventilation (p = .001).
Reduced incidence of bronchopulmonary dysplasia (p = .03), pulmonary hemorrhage (p = .02), and sepsis (p = .004) in the MIST group.
Shorter duration of CPAP support observed in the MIST group with reduced overall mortality (p = .042).
Length of oxygen therapy was similar in both groups.

Cite This Study

Suwethaa et al. (2026) studied this question.

synapsesocial.com/papers/698828fd0fc35cd7a8848f03 https://doi.org/10.1177/09732179261418764

View Full Paper

Ask AI

Bookmark

Implication

Randomised trial shows minimally invasive surfactant therapy reduces complications in preterm neonates with respiratory distress syndrome, suggesting a better clinical practice.

Minimally Invasive Surfactant Therapy Versus InSurE in Preterm Neonates of 28-34 Weeks of Gestation with Respiratory Distress Syndrome: A Randomised Controlled Trial

Discussion

Member takes

Implication

Key Points

Cite This Study

Minimally Invasive Surfactant Therapy Versus InSurE in Preterm Neonates of 28-34 Weeks of Gestation with Respiratory Distress Syndrome: A Randomised Controlled Trial

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider